Spikevax (Moderna mRNA-1273 COVID-19 vaccine) in COVID-19 prophylaxis (excluding children) - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias confirmed Covid-19, from 1st dosedetailed results COVE Moderna/NIH phase 3 (study 301), 2020 0.05 [0.03; 0.09]
0.05 [0.03 ; 0.09 ] COVE Moderna/NIH phase 3 (study 301), 2020 1 0% 28,207 NA not evaluable death D28detailed results Husby (Moderna), 2021 0.41 [0.37; 0.46]
0.41 [0.37 ; 0.46 ] Husby (Moderna), 2021 1 0% NA not evaluable deathsdetailed results COVE Moderna/NIH phase 3 (study 301), 2020 0.50 [0.02; 14.84]
0.50 [0.02 ; 14.84 ] COVE Moderna/NIH phase 3 (study 301), 2020 1 0% 28,207 NA not evaluable vaccine efficacy from randomization (ITT)detailed results COVE Moderna/NIH phase 3 (study 301), 2020 0.07 [0.04; 0.11]
0.07 [0.04 ; 0.11 ] COVE Moderna/NIH phase 3 (study 301), 2020 1 0% 29,148 NA not evaluable confirmed COVID (any severity)detailed results Butt, 2021 0.02 [0.01; 0.02]
Southern California (Tseng) - delta, 2022 0.05 [0.04; 0.06]
Southern California (Tseng) - omicron, 2022 0.70 [0.51; 0.95]
0.08 [0.01 ; 0.71 ] Butt, 2021, Southern California (Tseng) - delta, 2022, Southern California (Tseng) - omicron, 2022 3 99% 115,377 low not evaluable hospitalizationdetailed results Mayo Clinic (Puranik), 2021 0.19 [0.04; 0.81]
0.19 [0.04 ; 0.81 ] Mayo Clinic (Puranik), 2021 1 0% 45,828 NA not evaluable symptomatic Covid-19detailed results Andrejko, 2021 0.14 [0.06; 0.31]
Canada (Nasreen), 2021 0.08 [0.04; 0.15]
Chung, 2021 0.06 [0.03; 0.13]
COVE Moderna/NIH phase 3 (study 301), 2020 0.06 [0.03; 0.11]
Mayo Clinic (Puranik), 2021 0.24 [0.13; 0.43]
Nanduri, 2021 0.49 [0.44; 0.55]
Qatar (Tang), 2021 0.15 [0.10; 0.24]
0.14 [0.06 ; 0.30 ] Andrejko, 2021, Canada (Nasreen), 2021, Chung, 2021, COVE Moderna/NIH phase 3 (study 301), 2020, Mayo Clinic (Puranik), 2021, Nanduri, 2021, Qatar (Tang), 2021 7 95% 380,371 moderate serious severe COVID-19 occurrencedetailed results Canada (Nasreen), 2021 0.06 [0.03; 0.11]
COVE Moderna/NIH phase 3 (study 301), 2020 0.02 [0.00; 0.27]
Grannis, 2021 0.05 [0.03; 0.08]
Mayo Clinic (Puranik), 2021 0.19 [0.04; 0.81]
Qatar (Tang), 2021 0.07 [0.00; 1.37]
0.06 [0.04 ; 0.08 ] Canada (Nasreen), 2021, COVE Moderna/NIH phase 3 (study 301), 2020, Grannis, 2021, Mayo Clinic (Puranik), 2021, Qatar (Tang), 2021 5 0% 84,076 serious not evaluable serious adverse eventsdetailed results COVE Moderna/NIH phase 3 (study 301), 2020 1.04 [0.78; 1.40]
1.04 [0.78 ; 1.40 ] COVE Moderna/NIH phase 3 (study 301), 2020 1 0% 30,351 NA not evaluable adverse eventsdetailed results COVE Moderna/NIH phase 3 (study 301), 2020 1.14 [1.08; 1.20]
1.14 [1.08 ; 1.20 ] COVE Moderna/NIH phase 3 (study 301), 2020 1 0% 30,351 NA not evaluable convulsions/seizures detailed results Klein, 2021 1.04 [0.84; 1.29]
1.04 [0.84 ; 1.29 ] Klein, 2021 1 0% 150 NA not evaluable disseminated intravascular coagulation detailed results Klein, 2021 0.70 [0.39; 1.27]
0.70 [0.39 ; 1.27 ] Klein, 2021 1 0% 25 NA not evaluable Guillain-Barré syndrome detailed results Klein, 2021 0.70 [0.22; 2.27]
0.70 [0.22 ; 2.27 ] Klein, 2021 1 0% 6 NA not evaluable immune thrombocytopenia detailed results Klein, 2021 1.12 [0.64; 1.95]
1.12 [0.64 ; 1.95 ] Klein, 2021 1 0% 23 NA not evaluable ischemic strokedetailed results Klein, 2021 0.97 [0.87; 1.08]
0.97 [0.87 ; 1.08 ] Klein, 2021 1 0% 650 NA not evaluable Myocardial infarction detailed results Klein, 2021 1.02 [0.89; 1.17]
1.02 [0.89 ; 1.17 ] Klein, 2021 1 0% 375 NA not evaluable myocarditisdetailed results Husby (Moderna), 2021 3.92 [2.30; 6.68]
Klein, 2021 1.18 [0.78; 1.78]
2.12 [0.65 ; 6.89 ] Husby (Moderna), 2021, Klein, 2021 2 92% 39 moderate not evaluable pericarditis detailed results Klein, 2021 1.18 [0.78; 1.78]
1.18 [0.78 ; 1.78 ] Klein, 2021 1 0% 39 NA not evaluable pulmonary embolismdetailed results Klein, 2021 1.01 [0.86; 1.19]
1.01 [0.86 ; 1.19 ] Klein, 2021 1 0% 290 NA not evaluable Transverse myelitis detailed results Klein, 2021 1.45 [0.07; 31.68]
1.45 [0.07 ; 31.68 ] Klein, 2021 1 0% 1 NA not evaluable venous thromboembolism detailed results Klein, 2021 1.16 [1.00; 1.34]
1.16 [1.00 ; 1.34 ] Klein, 2021 1 0% 327 NA not evaluable VTE with thrombocytopeniadetailed results Klein, 2021 0.86 [0.58; 1.27]
0.86 [0.58 ; 1.27 ] Klein, 2021 1 0% 53 NA not evaluable cerebral venous sinus thrombosis (CVST)detailed results Klein, 2021 1.55 [0.33; 7.28]
McMurry, 2021 0.50 [0.02; 14.82]
1.27 [0.31 ; 5.21 ] Klein, 2021, McMurry, 2021 2 0% 686,456 serious not evaluable appendicitisdetailed results COVE Moderna/NIH phase 3 (study 301), 2020 0.67 [0.11; 3.99]
Klein, 2021 0.82 [0.73; 0.93]
0.82 [0.73 ; 0.92 ] COVE Moderna/NIH phase 3 (study 301), 2020, Klein, 2021 2 0% 30,842 critical not evaluable arthralgia, grade 3-4detailed results COVE Moderna/NIH phase 3 (study 301), 2020 18.37 [13.54; 24.91]
18.37 [13.54 ; 24.91 ] COVE Moderna/NIH phase 3 (study 301), 2020 1 0% 30,351 NA not evaluable Bell's palsydetailed results COVE Moderna/NIH phase 3 (study 301), 2020 3.00 [0.31; 28.83]
Klein, 2021 1.00 [0.86; 1.17]
Li X, 2022 0.99 [0.57; 1.73]
McMurry, 2021 0.20 [0.03; 1.33]
0.98 [0.73 ; 1.32 ] COVE Moderna/NIH phase 3 (study 301), 2020, Klein, 2021, Li X, 2022, McMurry, 2021 4 18% 30,652 serious not evaluable hypersensitivity, all termsdetailed results COVE Moderna/NIH phase 3 (study 301), 2020 1.41 [1.15; 1.72]
1.41 [1.15 ; 1.72 ] COVE Moderna/NIH phase 3 (study 301), 2020 1 0% 30,351 NA not evaluable lymphadenopathy, grade 3-4detailed results COVE Moderna/NIH phase 3 (study 301), 2020 1.00 [0.06; 15.97]
1.00 [0.06 ; 15.97 ] COVE Moderna/NIH phase 3 (study 301), 2020 1 0% 30,351 NA not evaluable musculoskeletal and connective tissue disorders, anydetailed results COVE Moderna/NIH phase 3 (study 301), 2020 1.00 [0.06; 15.97]
1.00 [0.06 ; 15.97 ] COVE Moderna/NIH phase 3 (study 301), 2020 1 0% 30,351 NA not evaluable myalgia, grade 3-4detailed results COVE Moderna/NIH phase 3 (study 301), 2020 27.64 [20.93; 36.50]
27.64 [20.93 ; 36.50 ] COVE Moderna/NIH phase 3 (study 301), 2020 1 0% 30,351 NA not evaluable fever, grade 3-4detailed results COVE Moderna/NIH phase 3 (study 301), 2020 43.29 [17.83; 105.10]
43.29 [17.83 ; 105.10 ] COVE Moderna/NIH phase 3 (study 301), 2020 1 0% 29,242 NA not evaluable local adverse reaction, any, dose 2detailed results COVE Moderna/NIH phase 3 (study 301), 2020 33.74 [31.59; 36.03]
33.74 [31.59 ; 36.03 ] COVE Moderna/NIH phase 3 (study 301), 2020 1 0% 29,235 NA not evaluable local adverse reaction, grade 3-4, dose 2detailed results COVE Moderna/NIH phase 3 (study 301), 2020 15.04 [11.83; 19.12]
15.04 [11.83 ; 19.12 ] COVE Moderna/NIH phase 3 (study 301), 2020 1 0% 29,235 NA not evaluable systemic adverse reaction, any, dose 2detailed results COVE Moderna/NIH phase 3 (study 301), 2020 6.69 [6.35; 7.05]
6.69 [6.35 ; 7.05 ] COVE Moderna/NIH phase 3 (study 301), 2020 1 0% 29,242 NA not evaluable systemic adverse reaction, grade 3-4, dose 2detailed results COVE Moderna/NIH phase 3 (study 301), 2020 9.50 [8.38; 10.77]
9.50 [8.38 ; 10.77 ] COVE Moderna/NIH phase 3 (study 301), 2020 1 0% 29,242 NA not evaluable 0.0 100.0 1.0 relative treatment effect www.metaEvidence.org 2024-09-26 19:37 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 89
- treatments: 755
- roots T: 290